Reprogram Biosciences raises seed funding: Evertrace spotted Rustam Esanov 442 days earlier

Reprogram Biosciences has raised seed funding. The company is developing experimental mRNA therapies for solid tumors.

Evertrace spotted Rustam Esanov, co-founder of Reprogram Biosciences, 442 days before the funding announcement.

Before the round

On 11 March 2025, Evertrace spotted the first signal of company formation for co-founder Rustam Esanov. The signal showed the company taking shape 442 days before its funding announcement.

What they’re building

Reprogram Biosciences is a preclinical biotechnology company studying how to make tumor cells help activate an immune response. Its approach uses mRNA-encoded gene combinations delivered into the tumor.

The team also uses an AI discovery platform to identify and prioritize potential therapeutic combinations. These are programs under development, rather than approved treatments.

The round

Reprogram announced the close of its seed financing, bringing total capital raised since founding to $6 million. The announcement does not separate the size of this round from that total. Investors include Unshackled Ventures, 1517 Fund and Narya. The funding supports its lead program, discovery work and manufacturing development.

Read the funding coverage →

Find your next investment before the round. Explore Evertrace →